(STAA) STAAR Surgical - Overview

Sector: Healthcare | Industry: Medical Instruments & Supplies | Exchange: NASDAQ (USA) | Market Cap: 1.594m USD | Total Return: 67.8% in 12m

Implantable Lenses, Delivery Systems, Refractive Surgery
Total Rating 51
Safety 50
Buy Signal 1.55
Medical Instruments & Supplies
Industry Rotation: +1.6
Market Cap: 1.59B
Avg Turnover: 21.6M
Risk 3d forecast
Volatility60.3%
VaR 5th Pctl9.65%
VaR vs Median-2.89%
Reward TTM
Sharpe Ratio1.00
Rel. Str. IBD89.8
Rel. Str. Peer Group93.2
Character TTM
Beta0.756
Beta Downside0.883
Hurst Exponent0.409
Drawdowns 3y
Max DD76.58%
CAGR/Max DD-0.27
CAGR/Mean DD-0.40
EPS (Earnings per Share) EPS (Earnings per Share) of STAA over the last years for every Quarter: "2021-03": 0.2, "2021-06": 0.27, "2021-09": 0.21, "2021-12": 0.19, "2022-03": 0.29, "2022-06": 0.42, "2022-09": 0.21, "2022-12": 0.14, "2023-03": 0.05, "2023-06": 0.4, "2023-09": 0.31, "2023-12": 0.16, "2024-03": -0.07, "2024-06": 0.15, "2024-09": 0.2, "2024-12": -0.69, "2025-03": -1, "2025-06": -0.13, "2025-09": 0.1614, "2025-12": 0.008, "2026-03": 0.2934,
EPS CAGR: -9.12%
EPS Trend: -38.0%
Last SUE: 0.79
Qual. Beats: 0
Revenue Revenue of STAA over the last years for every Quarter: 2021-03: 50.752, 2021-06: 62.367, 2021-09: 58.352, 2021-12: 59.001, 2022-03: 63.2, 2022-06: 81.101, 2022-09: 76.046, 2022-12: 64.044, 2023-03: 73.528, 2023-06: 92.306, 2023-09: 80.308, 2023-12: 76.273, 2024-03: 77.356, 2024-06: 99.005, 2024-09: 88.59, 2024-12: 48.95, 2025-03: 42.589, 2025-06: 44.32, 2025-09: 94.732, 2025-12: 57.801, 2026-03: 93.522,
Rev. CAGR: 3.87%
Rev. Trend: -24.3%
Last SUE: 1.18
Qual. Beats: 1

Warnings

Interest Coverage Ratio -1.3 is critical

Altman Z'' 0.87 < 1.0 - financial distress zone

Tailwinds

Supp Ema20, Leader, Confidence

Description: STAA STAAR Surgical

STAAR Surgical Company (STAA) specializes in the design and manufacture of phakic intraocular lenses and delivery systems used in refractive eye surgery. Its core product line, the Implantable Collamer Lens (ICL) family, provides surgical alternatives to laser-based procedures for correcting myopia, hyperopia, astigmatism, and presbyopia. The company operates a global distribution model, utilizing direct sales forces in major markets like the United States and Japan while leveraging independent distributors across China and Europe.

The refractive surgery sector is characterized by high barriers to entry due to stringent regulatory approval processes for medical implants. Unlike LASIK, which reshapes the cornea, STAAR’s business model focuses on additive lens technology, which is often marketed as a reversible procedure for patients with thin corneas or high refractive errors. Investors should consult ValueRay to analyze how these competitive moats impact long-term valuation.

Headlines to Watch Out For
  • China market demand volatility impacts overall revenue growth trajectory
  • EVO ICL adoption rates in United States drive market share expansion
  • Direct sales channel transition in Europe influences operating margin performance
  • Regulatory approval timelines for presbyopia lenses dictate future total addressable market
  • Consumer discretionary spending levels affect volume of elective refractive procedures
Piotroski VR‑10 (Strict) 3.0
Net Income: -21.0m TTM > 0 and > 6% of Revenue
FCF/TA: -0.12 > 0.02 and ΔFCF/TA -9.10 > 1.0
NWC/Revenue: 86.58% < 20% (prev 92.48%; Δ -5.90% < -1%)
CFO/TA -0.10 > 3% & CFO -46.3m > Net Income -21.0m
Net Debt (-94.6m) to EBITDA (2.91m): -32.52 < 3
Current Ratio: 5.12 > 1.5 & < 3
Outstanding Shares: last quarter (50.9m) vs 12m ago 3.15% < -2%
Gross Margin: 76.43% > 18% (prev 0.74%; Δ 7.57k% > 0.5%)
Asset Turnover: 63.93% > 50% (prev 61.03%; Δ 2.89% > 0%)
Interest Coverage Ratio: -1.33 > 6 (EBITDA TTM 2.91m / Interest Expense TTM 8.40m)
Altman Z'' 0.87
A: 0.56 (Total Current Assets 312.4m - Total Current Liabilities 61.0m) / Total Assets 451.1m
B: -0.32 (Retained Earnings -142.8m / Total Assets 451.1m)
C: -0.02 (EBIT TTM -11.2m / Avg Total Assets 454.2m)
D: -1.51 (Book Value of Equity -149.1m / Total Liabilities 98.8m)
Altman-Z'' Score: 0.87 = B
Beneish M -1.95
DSRI: 1.83 (Receivables 81.2m/42.7m, Revenue 290.4m/279.1m)
GMI: 0.97 (GM 76.43% / 74.00%)
AQI: 1.57 (AQ_t 0.09 / AQ_t-1 0.05)
SGI: 1.04 (Revenue 290.4m / 279.1m)
TATA: 0.06 (NI -21.0m - CFO -46.3m) / TA 451.1m)
Beneish M-Score: -1.95 (Cap -4..+1) = B
What is the price of STAA shares? As of May 19, 2026, the stock is trading at USD 32.31 with a total of 1,025,899 shares traded.
Over the past week, the price has changed by +16.10%, over one month by +26.56%, over three months by +84.00% and over the past year by +67.84%.
Is STAA a buy, sell or hold? STAAR Surgical has received a consensus analysts rating of 3.29. Therefor, it is recommend to hold STAA.
  • StrongBuy: 3
  • Buy: 0
  • Hold: 10
  • Sell: 0
  • StrongSell: 1
What are the forecasts/targets for the STAA price?
Analysts Target Price 27.1 -16.1%
STAAR Surgical (STAA) - Fundamental Data Overview as of 16 May 2026
P/E Forward = 95.2381
P/S = 5.4885
P/B = 3.8609
P/EG = 0.7622
Revenue TTM = 290.4m USD
EBIT TTM = -11.2m USD
EBITDA TTM = 2.91m USD
Long Term Debt = 38.4m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 6.10m USD (from shortTermDebt, last quarter)
Debt = 44.5m USD (corrected: LT Debt 38.4m + ST Debt 6.10m)
Net Debt = -94.6m USD (from netDebt column, last quarter)
Enterprise Value = 1.51b USD (1.59b + Debt 44.5m - CCE 131.9m)
Interest Coverage Ratio = -1.33 (Ebit TTM -11.2m / Interest Expense TTM 8.40m)
EV/FCF = -27.62x (Enterprise Value 1.51b / FCF TTM -54.5m)
FCF Yield = -3.62% (FCF TTM -54.5m / Enterprise Value 1.51b)
FCF Margin = -18.78% (FCF TTM -54.5m / Revenue TTM 290.4m)
Net Margin = -7.24% (Net Income TTM -21.0m / Revenue TTM 290.4m)
Gross Margin = 76.43% ((Revenue TTM 290.4m - Cost of Revenue TTM 68.4m) / Revenue TTM)
Gross Margin QoQ = 73.63% (prev 73.37%)
Tobins Q-Ratio = 3.34 (Enterprise Value 1.51b / Total Assets 451.1m)
Interest Expense / Debt = 18.90% (Interest Expense 8.40m / Debt 44.5m)
Taxrate = 36.65% (3.01m / 8.22m)
NOPAT = -7.07m (EBIT -11.2m * (1 - 36.65%)) [loss with tax shield]
Current Ratio = 5.12 (Total Current Assets 312.4m / Total Current Liabilities 61.0m)
Debt / Equity = 0.13 (Debt 44.5m / totalStockholderEquity, last quarter 352.4m)
Debt / EBITDA = -32.52 (Net Debt -94.6m / EBITDA 2.91m)
 Debt / FCF = 1.73 (negative FCF - burning cash) (Net Debt -94.6m / FCF TTM -54.5m)
 Total Stockholder Equity = 346.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -4.63% (Net Income -21.0m / Total Assets 451.1m)
RoE = -6.07% (Net Income TTM -21.0m / Total Stockholder Equity 346.7m)
RoCE = -2.90% (EBIT -11.2m / Capital Employed (Equity 346.7m + L.T.Debt 38.4m))
 RoIC = -2.05% (negative operating profit) (NOPAT -7.07m / Invested Capital 344.8m)
 WACC = 8.73% (E(1.59b)/V(1.64b) * Re(8.64%) + D(44.5m)/V(1.64b) * Rd(18.90%) * (1-Tc(0.37)))
Discount Rate = 8.64% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 44.95 | Cagr: 1.48%
 [DCF] Fair Price = unknown (Cash Flow -54.5m)
 EPS Correlation: -38.02 | EPS CAGR: -9.12% | SUE: 0.79 | # QB: 0
Revenue Correlation: -24.25 | Revenue CAGR: 3.87% | SUE: 1.18 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.27 | Chg30d=+36.25% | Revisions=+33% | Analysts=5
EPS next Quarter (2026-09-30): EPS=0.23 | Chg30d=+30.41% | Revisions=+0% | Analysts=5
EPS current Year (2026-12-31): EPS=0.53 | Chg30d=-4.66% | Revisions=+0% | GrowthEPS=+416.9% | GrowthRev=+39.4%
EPS next Year (2027-12-31): EPS=1.01 | Chg30d=+31.60% | Revisions=-11% | GrowthEPS=+92.1% | GrowthRev=+7.2%
[Analyst] Revisions Ratio: +33%